STAG2 and Ewing sarcoma: No enhanced sensitivity to inhibitors of mTOR (Everolimus) and tyrosine kinase (Imanitab, Sorafenib) was observed in STAG2 mutant glioblastoma, Ewing sarcoma and hTERT-positive retinal pigmented epithelial cells in Mondel et al.’s study [15].